A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis
NCT01723254
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
190
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergic Rhinitis
Interventions
BIOLOGICAL:
IGE-1
BIOLOGICAL:
IGE-2
BIOLOGICAL:
Saline
Sponsor
Pfizer